Mizuho Initiates Coverage on Maze Therapeutics (NASDAQ:MAZE)

Investment analysts at Mizuho started coverage on shares of Maze Therapeutics (NASDAQ:MAZE) in a research note issued to investors on Tuesday,Benzinga reports. The brokerage set an “outperform” rating and a $97.00 price target on the stock. Mizuho’s target price points to a potential upside of 115.27% from the company’s current price.

A number of other equities analysts have also issued reports on MAZE. Raymond James Financial started coverage on Maze Therapeutics in a research note on Thursday, November 13th. They issued an “outperform” rating and a $48.00 target price for the company. Wall Street Zen downgraded Maze Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, February 7th. HC Wainwright reissued a “buy” rating on shares of Maze Therapeutics in a research report on Wednesday, January 28th. Lifesci Capital raised shares of Maze Therapeutics to a “strong-buy” rating in a report on Thursday, December 18th. Finally, BTIG Research reiterated a “buy” rating and set a $46.00 price objective on shares of Maze Therapeutics in a research note on Monday. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Maze Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $54.63.

Maze Therapeutics Stock Up 0.5%

MAZE stock opened at $45.06 on Tuesday. The stock has a market capitalization of $2.17 billion, a PE ratio of -2.16 and a beta of 4.46. Maze Therapeutics has a 52 week low of $6.71 and a 52 week high of $49.25. The firm has a 50 day moving average of $44.00 and a 200 day moving average of $34.85.

Insider Buying and Selling at Maze Therapeutics

In other news, SVP Amy Bachrodt sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $46.04, for a total transaction of $230,200.00. Following the completion of the sale, the senior vice president owned 12,965 shares in the company, valued at $596,908.60. This trade represents a 27.83% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CMO Harold Bernstein sold 15,000 shares of the company’s stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $46.02, for a total value of $690,300.00. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 200,000 shares of company stock worth $8,254,792.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in MAZE. Royal Bank of Canada raised its stake in shares of Maze Therapeutics by 128.3% in the fourth quarter. Royal Bank of Canada now owns 646 shares of the company’s stock valued at $27,000 after acquiring an additional 363 shares in the last quarter. GF Fund Management CO. LTD. acquired a new stake in Maze Therapeutics during the fourth quarter worth approximately $39,000. Ameritas Investment Partners Inc. lifted its position in Maze Therapeutics by 82.6% in the third quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock valued at $42,000 after acquiring an additional 738 shares during the last quarter. Caitong International Asset Management Co. Ltd acquired a new position in Maze Therapeutics during the fourth quarter worth approximately $43,000. Finally, Russell Investments Group Ltd. raised its position in Maze Therapeutics by 947.8% in the 3rd quarter. Russell Investments Group Ltd. now owns 1,907 shares of the company’s stock valued at $49,000 after purchasing an additional 1,725 shares during the last quarter.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.